Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2017 Jul;9(Suppl 8):S799-S808.
doi: 10.21037/jtd.2017.05.09.

Salvage esophagectomy: safe therapeutic strategy?

Affiliations
Review

Salvage esophagectomy: safe therapeutic strategy?

Sara Jamel et al. J Thorac Dis. 2017 Jul.

Abstract

The objectives of this review were to assess both the short- and long-term clinical outcomes in patients managed with definitive chemoradiotherapy, and salvage esophagectomy subsequently in comparison to those neoadjuvant chemoradiotherapy followed by planned esophagectomy (NCRS) for esophageal cancer from published literature. Eleven studies comprising 1,906 patients were included, 563 in the salvage group and 1,343 in the NCRS group. Pooled analysis showed no significant difference between salvage and NCRS groups in overall survival [hazard ratio (HR) =1.17; 95% confidence interval (95% CI), 0.94-1.46, P=0.148], postoperative mortality [pooled odds ratios (POR) =1.12; 95% CI, 0.52-2.41, P=0.775], pulmonary complications (POR =1.24; 95% CI, 0.83-1.86, P=0.292) and positive resection margin incidence (POR =1.29; 95% CI, 0.94-1.76, P=0.114). However, within the salvage group there were increases in postoperative morbidity (POR =1.30; 95% CI, 1.00-1.67, P=0.046) and anastomotic leak (POR =1.88; 95% CI, 1.41-2.51, P<0.001). Herein we found that salvage esophagectomy has similar short- and long-term mortality in comparison to planned esophagectomy following neoadjuvant chemoradiotherapy. However, anastomotic leak is increased following salvage esophagectomy suggesting the need for this practice to be reserved for high volume surgeons within high volume centers.

Keywords: Esophageal cancer; chemotherapy; definitive chemotherapy; neoadjuvant chemotherapy; salvage esophagectomy.

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: The authors have no conflicts of interest to declare.

Figures

Figure 1
Figure 1
PRISMA search strategy.
Figure 2
Figure 2
Forrest plot showing no significant difference between the groups in overall survival (HR =1.17; 95% CI, 0.94–1.46, P=0.148). HR, hazard ratio.
Figure 3
Figure 3
Forrest plot showing no significant difference between the groups in postoperative mortality (POR =1.12; 95% CI, 0.52–2.41, P=0.775). POR, pooled odds ratios.
Figure 4
Figure 4
Forrest plot showing an increase in postoperative morbidity following salvage esophagectomy (POR =1.30, 95% CI, 1.00–1.67, P=0.046). POR, pooled odds ratios.
Figure 5
Figure 5
Forrest plot showing an increase in anastomotic leak following salvage esophagectomy (POR =1.88; 95% CI, 1.41–2.51, P<0.001). POR, pooled odds ratios.
Figure 6
Figure 6
Forrest plot showing no significant difference between the groups in pulmonary complications (POR =1.24; 95% CI, 0.83–1.86, P=0.292). POR, pooled odds ratios.
Figure 7
Figure 7
Forrest plot showing no significant difference between the groups in positive resection margin incidence (POR =1.29; 95% CI, 0.94–1.76, P=0.114). POR, pooled odds ratios.

References

    1. Mungo B, Molena D, Stem M, et al. Does neoadjuvant therapy for esophageal cancer increase postoperative morbidity or mortality? Dis Esophagus 2015;28:644-51. 10.1111/dote.12251 - DOI - PMC - PubMed
    1. International Agency for Research on Cancer. Oesophageal cancer: estimated incidence, mortality and prevalence worldwide in 2012.
    1. Allum WH, Stenning SP, Bancewicz J, et al. Long-term results of a randomized trial of surgery with or without preoperative chemotherapy in esophageal cancer. J Clin Oncol 2009;27:5062-7. 10.1200/JCO.2009.22.2083 - DOI - PubMed
    1. Tepper J, Krasna MJ, Niedzwiecki D, et al. Phase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB 9781. J Clin Oncol 2008;26:1086-92. 10.1200/JCO.2007.12.9593 - DOI - PMC - PubMed
    1. Sjoquist KM, Burmeister BH, Smithers BM, et al. Survival after neoadjuvant chemotherapy or chemoradiotherapy for resectable oesophageal carcinoma: an updated meta-analysis. Lancet Oncol 2011;12:681-92. 10.1016/S1470-2045(11)70142-5 - DOI - PubMed

LinkOut - more resources